Tyrosine kinase inhibitorFDA-approvedFirst-line
Zelboraf
Generic name: vemurafenib
How it works
Blocks the BRAF V600E mutation in cancer cells, which is a genetic abnormality that can lead to cancer growth.
Cancer types
Melanoma— BRAF V600E mutation-positive
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 15 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combining Palbociclib and Vemurafenib in Metastatic Melanoma Treatment | Melanoma | phase-1/2 | The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response. | Source → |
| Vemurafenib May Help Hairy Cell Leukemia Patients Before Standard Treatment | Leukemia | observational | After a standard course of cladribine chemotherapy, 18 patients (90%) experienced complete clinical remission and 2 patients (10%) experienced partial remission with residual splenomegaly. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.